BiotechTube

Esomeprazole + Matching placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Symptomatic Gastroesophageal Reflux Disease (sGERD)

Conditions

Symptomatic Gastroesophageal Reflux Disease (sGERD)

Trial Timeline

Mar 1, 2003 → Feb 1, 2004

NCT ID
NCT00626535

About Esomeprazole + Matching placebo

Esomeprazole + Matching placebo is a phase 3 stage product being developed by AstraZeneca for Symptomatic Gastroesophageal Reflux Disease (sGERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00626535. Target conditions include Symptomatic Gastroesophageal Reflux Disease (sGERD).

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Gastroesophageal Reflux Disease (sGERD) were approved

Approved (3) Terminated (4) Active (9)
❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
🔄ISV-305Sun PharmaceuticalPhase 3
🔄rabeprazole sodium + PlaceboEisaiPhase 3
🔄Pasireotide + OctreotideNovartisPhase 3
✅valsartanNovartisApproved
🔄Apixaban + Standard of carePfizerPhase 3
❌Azithromycin plus chloroquinePfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00626535Phase 3Completed

Competing Products

20 competing products in Symptomatic Gastroesophageal Reflux Disease (sGERD)

See all competitors
ProductCompanyStageHype Score
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ISV-305Sun PharmaceuticalPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
DFV890 + PlaceboNovartisPhase 2
35
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
35
Pasireotide + OctreotideNovartisPhase 3
40
TegaserodNovartisPhase 2
35
valsartanNovartisApproved
43
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Epoetin biosimilarPfizerPre-clinical
26
Apixaban + Standard of carePfizerPhase 3
40
Azithromycin plus chloroquinePfizerPhase 3
32
MavacamtenBristol Myers SquibbApproved
50
Aficamten + PlaceboSanofiPhase 3
44
Vandetanib 300 mgSanofiPre-clinical
26
REGN7508 + Acetylsalicylic Acid (ASA) + PlaceboRegeneron PharmaceuticalsPhase 3
47
Rivaroxaban + PlaceboBayerPhase 3
37
Droxidopa capsules + Placebo capsulesLundbeckApproved
40